



ABN: 12 107 903 159

ASX Announcement

Helicon Director Resigns

Perth, April 30th, 2009. HELICON GROUP LIMITED (ASX code: HCG) announces that Dr Chris Brown has resigned as Non Executive Director of Helicon Group Limited.

Dr. Brown joined the Helicon Board upon the Company's incorporation in February 2004 and was a major driving force in the development of the Company's strategy and evolution. He has resigned for personal reasons unrelated to his Helicon directorship.

"On behalf of Helicon Group and the Board, I would like to thank Chris for his contribution over the last 5 years and to express our regret at his departure. His business acumen, together with his experience and connections in China have been invaluable." commented Peter Abrahamson, Helicon's CEO.

About the Helicon Group

Helicon is listed on the Australian Securities Exchange. The Company's business is to identify and exploit niche market opportunities in the biomedical markets in North Asia, specifically China and to participate in the significant growth that has been projected for these markets in the next 25 years.

Helicon looks for "Special Situations" for advanced Western biopharmaceutical products that are not available in China or other North Asian Markets or where there are market needs that are not being adequately provided for.

Helicon's product partners are likely to be innovative small to medium sized pharmaceutical and healthcare enterprises focused largely on Western Markets. Helicon seeks exclusive licenses for the designated markets and utilises a low cost operating overhead base in combination with established channel partners for product registration, distribution, marketing and sales.

For further information please contact:

Peter Abrahamson
Helicon Group Limited
Suite 3, 257 York Street Subiaco WA 6008
Tel+61 411 336 330
Email: p.abrahamson@helicongroup.com.au